Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Pimecrolimus

Classification: A

Drug products: Elidel, Elidel®

ATC code: D11AH02

Substances: pimecrolimus

Summary

One study showed similar effect of treatment with pimecrolimus in men and women with Behcet’s disease. Controlled studies on differences between men and women regarding safety and pharmacokinetics are however lacking.
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No difference between men and women has been shown for transdermal absorption in general [1].

Effects

A randomized double-blind placebo-controlled study (41 men, 49 women) of treatment with pimecrolimus cream in genital ulcers from Behcet’s disease showed similar effect in men and women [2].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of pimecrolimus have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2017-03-24

References

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
  2. Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010;13:253-8. PubMed
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-03-23.] länk

Authors: Maria Enghag

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson